Peptide Atlas · Peptide

Davunetide

Davunetide (NAP, AL-108) is an intranasal peptide that stabilized microtubules and reduced tau phosphorylation in preclinical studies; in a 52-week phase 2/3 trial in 313 people with progressive supranuclear palsy it did not differ from placebo on either primary measure.

established

provisional
8 aa
PubChem 9832404
2 citations
0 discussions
0 followers
ADNF fragment
AL-108
AL-208
NAP
NAPVSIPQ
activity-dependent neuroprotective protein fragment

Follow this molecule Ask the Hunter-Gatherer

What the evidence says

six tiers, never blended

established — replicated in humans, or settled by a regulator

every claim resolves to its source

All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.

Sequence

N A P V S I P Q

PubChem CID 9832404: Davunetide, C36H60N10O12, 824.9 g/mol. · 8 residues · source pubchem:9832404, fetched not recalled.

Evidence, kept apart

The Atlas never mixes evidence types into one blob. Each claim below carries the tier it actually sits in; an unresolved citation is shown and does not move the page.

Evidence map for Davunetide. Tier reflects study design, not enthusiasm.
Claim	Tier	Source
Davunetide in schizophrenia: no cognitive effect, functional capacity improved (RCT, n=63)	emerging	pmid 22169248
Davunetide was not effective in progressive supranuclear palsy (phase 2/3 RCT)	established	pmid 24873720

Unanswered questions

No open questions on file. Either everything about this molecule is known, or nobody has admitted what is not.

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.